EUCTR2011-006314-14-GB进行中（未招募）1 期
A Randomised, Double-blind, Placebo-controlled, Phase I/II Trial of RNActive®-derived Cancer Vaccine (CV9104) in Asymptomatic or Minimally Symptomatic Patients with Metastatic Castrate-refractory Prostate Cancer
CureVac AG0 个研究点目标入组 204 人开始时间: 2012年8月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 204
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Male, age = 18 years
- •2. Histologically confirmed castrate-refractory metastatic adenocarcinoma of the prostate with progressive disease
- •- after surgical castration; or during androgen suppression therapy, including a gonadoptropinreleasing hormone (GNRH) agonist or antagonist
- •- after at least 1 second-line anti-hormonal manipulation (e.g. antiandrogen; including combined androgen blockade followed by antiandrogen withdrawal)
- •- a serum testosterone level of < 50 ng/dL or < 1.7 nmol/L.
- •Progression will be confirmed either
- •- radiologically (nodal or other soft tissue progression, appearance of 2 or more new lesions on bone scan - to be confirmed by other imaging ifflare or trauma is suspected); or
- •- by 2 consecutive rises of PSA, measured at least 1 week apart, resulting at least in a 50% increase over the nadir and PSA > 2 ng/mL. The last of these PSA values must have been measured within 2 months prior to start of screening and
- •- In patients having received initial combined androgen blockade or haveshown a decline in PSA for = 3 months after administration of an antiandrogen an antiandrogen withdrawal response must have been excluded after discontinuation of
- •antiandrogen therapy (e.g. bicalutamide, flutamide or nilutamide) for at least 6 weeks prior to randomisation. Patients with a confirmedprogression (PCWG2) after an antiandrogen withdrawal response are eligible. All patients must have discontinued antiandrogen treatment prior to randomization
- •3. Metastatic disease confirmed by imaging (bone scan, computed tomography [CT] or magnetic-resonance imaging [MRI]); ambiguous bone scan results should be confirmed by a second method.
- •4. Performance status: Eastern Cooperative Oncology Group (ECOG) 0 to 1.
- •5. Patients should be unlikely to need subsequent systemic therapy within the next 4 weeks (safety lead-in) or the next 3 months (randomised portion), in the opinion of the investigator.
- •6. Adequate organ function:
- •- Bone marrow function: haemoglobin =100 g/L; white
- •blood cell count =3.0 × 1.000.000.000/L; lymphocyte count =0.8 × 1.000.000.000/L; absolute neutrophil count =1.5 × 1.000.000.000/L; platelet count =100 × 1.000.000.000/L.
- •- Hepatic: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =2.5 × upper limit of normal; bilirubin =1.5 × upper limit of normal.
- •- Renal: creatinine =2 mg/dL and creatinine clearance
- •=45 mL/min/1.73m2.
- •7. Men of child producing potential must agree that together with their female partners they will use a highly effective method of contraception as defined in ICH (M3) resulting in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Those methods include implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomy. The contraception should be applied until 1 month after the last vaccination.
- •8. Patients requiring bisphosphonates or denosumab at the time of registration into the trial are eligible as long as therapy is initiated at least 28 days prior to first study treatment administration and it must be cont
排除标准
- •1. Previous immunotherapy for PCA (e.g. sipuleucel-T
- •[Provenge®], experimental cancer vaccines or ipilimumab [Yervoy®]).
- •2. Estimated life expectancy of < 6 months due to PCA or concomitant disease.
- •3. Treatment with any investigational anticancer agents within 4 weeks or 5 half-lives according to what gives the longer range prior to first dose of study drug.
- •4. Acute pathologic fracture or spinal cord compression at screening.
- •5. Systemic immunosuppressive agents including systemic steroids or immunomodulating agents including herbal remedies (e.g. mistletoe extract) for the previous 28 days prior to the start of treatment or need for such immunosuppressive/-modulating treatment, exceptglucocorticoid replacement therapy for adrenal insufficiency. For other conditions where steroid therapy is allowed, see section on prior and concomitant therapy (Section 6.3).
- •6. Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection (upper arms or thighs) preventing the administration of i.d. injections into areas of healthy skin.
- •7. Concurrent major surgery or planned surgery.
- •8. Prior splenectomy or prior allogeneic bone marrow
- •transplant.
- •9. History of or current autoimmune disorders such as sarcoidosis, lupus erythematosus, rheumatoid arthritis,
- •glomerulonephritis systemic vasculitis, autoimmune
- •hepatitis, Sjögren syndrome, scleroderma, polymyalgia rheumatica, arteriitis temporalis, calcinosis, Raynauds disease, esophageal dysmotility, sclerodactyly and telangiectasia (CREST) syndrome (limited cutaneous scleroderma), dermatomyositis, Morbus Crohn and colitis ulcerosa except autoimmune thyroiditis with only thyroid hormone replacement or vitiligo or Diabetes Mellitus type 1.
- •10. Primary or secondary immune deficiency.
- •11. Allergies to any components of the study drug including allergy to protamine sulfate (e.g. allergy to protamine-containing insulins) or fish allergy.
- •12. Allergies to penicillins or other ß-lactam antibiotics
- •13. Active infections requiring anti-infectious therapy at the time of randomization.
- •14. Seropositive for human immunodeficiency virus, hepatitis B virus (except after hepatitis B vaccination) or hepatitis C virus infection.
- •15. Uncontrolled urinary retention or hydronephrosis (to be confirmed by ultrasound, bladder scan or other adequate imaging method). Patients with urinary retention can be enrolled after adequate treatment, see section 6.3.
- •16. Uncontrolled medical condition considered as high risk for the treatment with an investigational drug (e.g. unstable Diabetes Mellitus, vena-cava-syndrome, uncontrolled pleural effusion, acute pulmonary embolism).
- •17. Known brain metastases or leptomeningeal involvement.
- •18. Symptomatic congestive heart failure (New York Heart Association 3 or 4), unstable angina pectoris or myocardial infarction, significant cardiac arrhythmia, history of stroke or transient ischemic attack, all within 6 months prior to enrolment or severe hypertension according to WHO criteria or uncontrolled hypertension at the time of enrolment (systolic blood pressure = 180 mm Hg).
- •19. History of sei
研究者
相似试验
招募中
1 期
A Randomised, Double-blind, Placebo-controlled, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Subcutaneous, Ascending Single and Multiple Doses of AP13 in Healthy AdultsPulmonary HypertensionACTRN12624000086561Apollo Therapeutics70
进行中（未招募）
1 期
ot applicableMetastatic Castrate-refractory Prostate CancerMedDRA version: 18.1Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-006314-14-CZCureVac AG200
进行中（未招募）
1 期
ot applicableEUCTR2011-006314-14-DECureVac AG200
进行中（未招募）
1 期
A Phase 2 Study to Assess the Efficacy and Safety of Orally Administered DS107 in a once daily doseof 2g in Haemodialysis Patients with Moderate to Severe Uremic PruritusModerate to Severe Uremic PruritusMedDRA version: 20.0Level: LLTClassification code 10060884Term: Uremic pruritusSystem Organ Class: 100000004858EUCTR2017-004098-15-EEDS Biopharma110
招募中
3 期
Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Ovarian Cancer Following Response to First-line Platinum-based chemotherapyCTRI/2021/08/035759AstraZeneca AB